Kura Oncology, Inc. KURA
Kura Oncology, Inc. (Nasdaq: KURA) is an oncology drug developer. Its lead program, KOMZIFTI (ziftomenib), is in Phase 3 for relapsed/refractory NPM1-mutated AML. Its next catalyst on record is ziftomenib: KOMET-007 data (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ziftomenib — KOMET-007 data (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| KOMZIFTI | NPM1-m AML | small molecule | Approved |
| ziftomenib (KOMET-017) | AML frontline | small molecule | Phase 3 |
| ziftomenib (KOMET-007) | AML combinations | small molecule | Phase 2 |
| darlifarnib | head and neck / solid tumors | small molecule | Phase 1 |
| KOMET-015 | GIST | small molecule | Phase 1 |
| KO-7246 | oncology | small molecule | Pre-clinical |
Recent results and decisions
- May 12, 2026started First patient dosed in Japanese registrational Phase 2 trial of ziftomenib in R/R NPM1-m AML.
Japanese Registrational Trial: First patient dosed in Phase 2 trial (jRCT2031250550) for treatment of R/R NPM1-m AML
Filing - May 12, 2026positive Proof-of-mechanism data: 44% ORR, 94% DCR and tumor shrinkage in 75% of patients (IKCS 2026).
44% objective response rate (ORR)
Filing - Nov 13, 2025approval FDA granted full approval to KOMZIFTI (ziftomenib) for adults with R/R NPM1-mutated AML (recap; approved Nov 13, 2025).
KOMZIFTI was granted full approval by the U.S. Food and Drug Administration (FDA) for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible NPM1 mutation who have no satisfactory alternative treatment options.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.